VYNE Therapeutics to Participate in March Investor Conferences
VYNE Therapeutics (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, has announced its management team's upcoming participation in two investor conferences scheduled for March. The company, which specializes in developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need, will make these presentations available through webcasts.
The company has confirmed that webcast replays will be accessible on the VYNE website for a 90-day period following each event. This initiative demonstrates VYNE's commitment to maintaining transparency with investors and sharing updates about their development pipeline.
VYNE Therapeutics (Nasdaq: VYNE), un'azienda biofarmaceutica in fase clinica, ha annunciato la prossima partecipazione del suo team di gestione a due conferenze per investitori previste per marzo. L'azienda, specializzata nello sviluppo di terapie differenziate per condizioni infiammatorie croniche e mediate dal sistema immunitario con un elevato bisogno insoddisfatto, render脿 disponibili queste presentazioni tramite webcast.
L'azienda ha confermato che le registrazioni dei webcast saranno accessibili sul sito web di VYNE per un periodo di 90 giorni dopo ciascun evento. Questa iniziativa dimostra l'impegno di VYNE a mantenere la trasparenza con gli investitori e a condividere aggiornamenti sul loro pipeline di sviluppo.
VYNE Therapeutics (Nasdaq: VYNE), una empresa biofarmac茅utica en etapa cl铆nica, ha anunciado la pr贸xima participaci贸n de su equipo de gesti贸n en dos conferencias para inversores programadas para marzo. La empresa, que se especializa en el desarrollo de terapias diferenciadas para condiciones inflamatorias cr贸nicas y mediadas por el sistema inmunol贸gico con una alta necesidad insatisfecha, har谩 que estas presentaciones est茅n disponibles a trav茅s de webcasts.
La empresa ha confirmado que las repeticiones de los webcasts estar谩n accesibles en el sitio web de VYNE durante un per铆odo de 90 d铆as despu茅s de cada evento. Esta iniciativa demuestra el compromiso de VYNE con la transparencia hacia los inversores y la actualizaci贸n sobre su pipeline de desarrollo.
VYNE Therapeutics (Nasdaq: VYNE)鞚� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 3鞗旍棎 鞓堨爼霅� 霊� 臧滌潣 韴瀽鞛� 須岇潣鞐� 瓴届榿歆� 韺�鞚� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 毵岇劚 鞐检 氚� 氅挫棴 毵り皽 歆堩櫂鞐� 雽�頃� 彀硠頇旊悳 旃橂氩� 臧滊皽鞚� 鞝勲鞙茧 頃橂姅 鞚� 須岇偓電� 鞚措煬頃� 氚滍憸毳� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
須岇偓電� 臧� 鞚措菠韸� 頉� 90鞚� 霃欖晥 VYNE 鞗轨偓鞚错姼鞐愳劀 鞗轨簮鞀ろ姼 鞛儩鞚� 鞚挫毄頃� 靾� 鞛堧嫟瓿� 頇曥澑頄堨姷雼堧嫟. 鞚� 鞚措媹靺旐嫲敫岆姅 韴瀽鞛愳檧鞚� 韴獏靹膘潉 鞙犾頃橁碃 臧滊皽 韺岇澊頂勲澕鞚胳棎 雽�頃� 鞐呺嵃鞚错姼毳� 瓿奠湢頃橂牑電� VYNE鞚� 鞚橃毳� 氤挫棳欷嶋媹雼�.
VYNE Therapeutics (Nasdaq: VYNE), une entreprise biopharmaceutique en phase clinique, a annonc茅 la prochaine participation de son 茅quipe de direction 脿 deux conf茅rences pour investisseurs pr茅vues en mars. L'entreprise, sp茅cialis茅e dans le d茅veloppement de th茅rapies diff茅renci茅es pour des conditions inflammatoires chroniques et m茅di茅es par le syst猫me immunitaire avec un fort besoin non satisfait, mettra ces pr茅sentations 脿 disposition via des webcasts.
L'entreprise a confirm茅 que les rediffusions des webcasts seront accessibles sur le site web de VYNE pendant une p茅riode de 90 jours apr猫s chaque 茅v茅nement. Cette initiative d茅montre l'engagement de VYNE 脿 maintenir la transparence envers les investisseurs et 脿 partager des mises 脿 jour concernant leur pipeline de d茅veloppement.
VYNE Therapeutics (Nasdaq: VYNE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die bevorstehende Teilnahme seines Managementteams an zwei Investorenkonferenzen im M盲rz angek眉ndigt. Das Unternehmen, das sich auf die Entwicklung differenzierter Therapien f眉r chronisch entz眉ndliche und immunvermittelte Erkrankungen mit einem hohen ungedeckten Bedarf spezialisiert hat, wird diese Pr盲sentationen 眉ber Webcasts verf眉gbar machen.
Das Unternehmen hat best盲tigt, dass die Aufzeichnungen der Webcasts f眉r einen Zeitraum von 90 Tagen nach jeder Veranstaltung auf der VYNE-Website zug盲nglich sein werden. Diese Initiative zeigt das Engagement von VYNE, Transparenz gegen眉ber den Investoren zu wahren und Updates 眉ber ihre Entwicklungs-Pipeline zu teilen.
- None.
- None.
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (鈥淰YNE鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE鈥檚 management will participate in two investor conferences in March.
Details are as follows:
| TD Cowen 45th Annual Health Care Conference, Boston, MA | ||
| Conference Date: | 听 | March 4, 2025 |
| Format: | 听 | Fireside chat and one-on-one meetings |
| Fireside Chat Timing: | 听 | Tuesday, March 4, 2025, 11:10 AM ET |
| Registration:听 | 听 | |
| 听 | 听 | 听 |
| Leerink Partners Global Healthcare Conference, Miami, FL | ||
| Conference Date: | 听 | March 11, 2025 |
| Format: | 听 | One-on-one meetings |
| 听 | 听 | 听 |
A webcast replay will be available on the VYNE website for 90 days following the event.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE鈥檚 unique and proprietary BET inhibitors, which comprise its InhiBET鈩� platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.听
For more information about VYNE Therapeutics Inc. or its product candidates, visit . VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE鈥檚 website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (鈥淪EC鈥�), public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
FAQ
When will VYNE Therapeutics participate in the upcoming investor conferences?
How long will the VYNE conference webcasts be available for replay?
What is VYNE Therapeutics' current business focus?
Where can investors access VYNE's March 2025 conference presentations?
